2026 Q1 -tulosraportti
Vain PDF
107 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenGot some help from AI to understand the result from the last test 2a. You are absolutely right in your clarification – and that is a very important detail. The primary goal (primary endpoint) for the entire patient group as a whole did not reach statistical significance over placebo at week 4. The reason why the company and the market nevertheless considered the study a success is due to the results in the specific subgroups and doses:The low dose failed: The lowest dose of 10 mg provided no clinically relevant improvement. This pulled down the overall average. Strong placebo effect at the start: At week 4, the placebo group experienced a significant improvement, which made it difficult for the medicine to statistically differentiate itself across the entire group. Statistical success at week 8: The placebo effect diminished over time. At week 8, a combination of the two highest doses (25 mg and 50 mg) showed a statistically significant improvement compared to placebo (p<0.05).Highest dose (50 mg): Among patients with moderate erectile dysfunction, 31% achieved a full effect (normalized function) in the 50 mg group, compared to 0% in the placebo group. Dicot Pharma's CEO therefore downplayed the missed primary endpoint because the study was a smaller phase 2a "Proof of Concept" study designed to find the right dose. The company is now using the data to directly pursue the higher doses in the upcoming phase 2b study.
·7 t sittenIncreased to DICOT PHARMA TO-7 5,700,000 units. Feels very good. Now have few of the shares but maybe can get more later.
·1 päivä sittenWhat do people think about the upcoming report?
Nothing special, what could make the stock surge towards 0.30-0.50 is probably what is being said about phase 2B……
·3 päivää sittenIf LIB-01 were later to show effect also in, for example, female sexual dysfunction/desire problems, the market could become significantly larger than the current ED market. Currently, there is nothing to indicate that Dicot has tested LIB-01 on women. Dicot still describes LIB-01 as a drug for erectile dysfunction and premature ejaculation in men. The preclinical LIB-01 studies have mainly used male rats and measured erectile function/sexual behavior. But: there are two things that make a future female indication scientifically interesting. 1. LIB-01 appears to affect the melanocortin/MC4R system Dicot has shown that LIB-01 affects gene expression linked to MC4R signaling, and the company describes MC4R as a central part of the nervous system's regulation of sexual function. And here it gets really interesting: Research on female mice shows that MC4R signaling is actually involved in female sexual receptivity. When MC4R was absent, the female mice's sexual receptivity decreased, while restoration of MC4R signaling normalized or improved the behavior. Even stronger is that MC4R agonism has been tested on real women with HSDD (hypoactive sexual desire disorder). In a randomized, placebo-controlled crossover study with 31 women, the MC4R agonist bremelanotide increased self-reported sexual desire for up to 24 hours compared to placebo. This means that the biological target mechanism itself, which Dicot says LIB-01 affects, is already validated for female sexual function.
There is no long-term and sustainable profit in creating false hopes based on pure speculation. Better to proceed from established facts. Dicot already has an enormous market for its small company, and that is more than enough for enormous profits.
·5.8.Why has short selling been stopped?Not shortable... But there are still shares that are shorted. Does that mean that it cannot be Shorted more than just those shares that are already shorted?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
107 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenGot some help from AI to understand the result from the last test 2a. You are absolutely right in your clarification – and that is a very important detail. The primary goal (primary endpoint) for the entire patient group as a whole did not reach statistical significance over placebo at week 4. The reason why the company and the market nevertheless considered the study a success is due to the results in the specific subgroups and doses:The low dose failed: The lowest dose of 10 mg provided no clinically relevant improvement. This pulled down the overall average. Strong placebo effect at the start: At week 4, the placebo group experienced a significant improvement, which made it difficult for the medicine to statistically differentiate itself across the entire group. Statistical success at week 8: The placebo effect diminished over time. At week 8, a combination of the two highest doses (25 mg and 50 mg) showed a statistically significant improvement compared to placebo (p<0.05).Highest dose (50 mg): Among patients with moderate erectile dysfunction, 31% achieved a full effect (normalized function) in the 50 mg group, compared to 0% in the placebo group. Dicot Pharma's CEO therefore downplayed the missed primary endpoint because the study was a smaller phase 2a "Proof of Concept" study designed to find the right dose. The company is now using the data to directly pursue the higher doses in the upcoming phase 2b study.
- ·7 t sittenIncreased to DICOT PHARMA TO-7 5,700,000 units. Feels very good. Now have few of the shares but maybe can get more later.
- ·1 päivä sittenWhat do people think about the upcoming report?Nothing special, what could make the stock surge towards 0.30-0.50 is probably what is being said about phase 2B……
- ·3 päivää sittenIf LIB-01 were later to show effect also in, for example, female sexual dysfunction/desire problems, the market could become significantly larger than the current ED market. Currently, there is nothing to indicate that Dicot has tested LIB-01 on women. Dicot still describes LIB-01 as a drug for erectile dysfunction and premature ejaculation in men. The preclinical LIB-01 studies have mainly used male rats and measured erectile function/sexual behavior. But: there are two things that make a future female indication scientifically interesting. 1. LIB-01 appears to affect the melanocortin/MC4R system Dicot has shown that LIB-01 affects gene expression linked to MC4R signaling, and the company describes MC4R as a central part of the nervous system's regulation of sexual function. And here it gets really interesting: Research on female mice shows that MC4R signaling is actually involved in female sexual receptivity. When MC4R was absent, the female mice's sexual receptivity decreased, while restoration of MC4R signaling normalized or improved the behavior. Even stronger is that MC4R agonism has been tested on real women with HSDD (hypoactive sexual desire disorder). In a randomized, placebo-controlled crossover study with 31 women, the MC4R agonist bremelanotide increased self-reported sexual desire for up to 24 hours compared to placebo. This means that the biological target mechanism itself, which Dicot says LIB-01 affects, is already validated for female sexual function.There is no long-term and sustainable profit in creating false hopes based on pure speculation. Better to proceed from established facts. Dicot already has an enormous market for its small company, and that is more than enough for enormous profits.
- ·5.8.Why has short selling been stopped?Not shortable... But there are still shares that are shorted. Does that mean that it cannot be Shorted more than just those shares that are already shorted?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
107 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenGot some help from AI to understand the result from the last test 2a. You are absolutely right in your clarification – and that is a very important detail. The primary goal (primary endpoint) for the entire patient group as a whole did not reach statistical significance over placebo at week 4. The reason why the company and the market nevertheless considered the study a success is due to the results in the specific subgroups and doses:The low dose failed: The lowest dose of 10 mg provided no clinically relevant improvement. This pulled down the overall average. Strong placebo effect at the start: At week 4, the placebo group experienced a significant improvement, which made it difficult for the medicine to statistically differentiate itself across the entire group. Statistical success at week 8: The placebo effect diminished over time. At week 8, a combination of the two highest doses (25 mg and 50 mg) showed a statistically significant improvement compared to placebo (p<0.05).Highest dose (50 mg): Among patients with moderate erectile dysfunction, 31% achieved a full effect (normalized function) in the 50 mg group, compared to 0% in the placebo group. Dicot Pharma's CEO therefore downplayed the missed primary endpoint because the study was a smaller phase 2a "Proof of Concept" study designed to find the right dose. The company is now using the data to directly pursue the higher doses in the upcoming phase 2b study.
- ·7 t sittenIncreased to DICOT PHARMA TO-7 5,700,000 units. Feels very good. Now have few of the shares but maybe can get more later.
- ·1 päivä sittenWhat do people think about the upcoming report?Nothing special, what could make the stock surge towards 0.30-0.50 is probably what is being said about phase 2B……
- ·3 päivää sittenIf LIB-01 were later to show effect also in, for example, female sexual dysfunction/desire problems, the market could become significantly larger than the current ED market. Currently, there is nothing to indicate that Dicot has tested LIB-01 on women. Dicot still describes LIB-01 as a drug for erectile dysfunction and premature ejaculation in men. The preclinical LIB-01 studies have mainly used male rats and measured erectile function/sexual behavior. But: there are two things that make a future female indication scientifically interesting. 1. LIB-01 appears to affect the melanocortin/MC4R system Dicot has shown that LIB-01 affects gene expression linked to MC4R signaling, and the company describes MC4R as a central part of the nervous system's regulation of sexual function. And here it gets really interesting: Research on female mice shows that MC4R signaling is actually involved in female sexual receptivity. When MC4R was absent, the female mice's sexual receptivity decreased, while restoration of MC4R signaling normalized or improved the behavior. Even stronger is that MC4R agonism has been tested on real women with HSDD (hypoactive sexual desire disorder). In a randomized, placebo-controlled crossover study with 31 women, the MC4R agonist bremelanotide increased self-reported sexual desire for up to 24 hours compared to placebo. This means that the biological target mechanism itself, which Dicot says LIB-01 affects, is already validated for female sexual function.There is no long-term and sustainable profit in creating false hopes based on pure speculation. Better to proceed from established facts. Dicot already has an enormous market for its small company, and that is more than enough for enormous profits.
- ·5.8.Why has short selling been stopped?Not shortable... But there are still shares that are shorted. Does that mean that it cannot be Shorted more than just those shares that are already shorted?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt